File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: One-year treatment of entecavir results in reduction in intrahepatic covalently closed circular DNA level

TitleOne-year treatment of entecavir results in reduction in intrahepatic covalently closed circular DNA level
Authors
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 56th Annual Meeting and Postgraduate Course of the American Association of Liver Diseases (AASLD), San Francisco, CA., 11-15 November 2005. In Hepatology, 2005, v. 42 suppl. S1, p. 573A, abstract no. 960 How to Cite?
AbstractBACKGROUND: Two phase 3, multicenter, double-blind trials on HBeAg-positive and HBeAg-negative patients demonstrate that, compared with lamivudine, entecavir is superior in inducing histologic improvement, serum HBV DNA suppression and transaminase normalization. Since intrahepatic HBV DNA and covalently closed circular (ccc) DNA are important for control of viral replication, the efficacy of entecavir vs. lamivudine in achieving suppression of these entities should be studied. METHODS AND PATIENTS: The patients involved in this study were recruited from patients participating in the two phase 3 entecavir trials at our center in Hong Kong. Forty chronic hepatitis B patients (14 HBeAg-positive and 26 anti-HBe-positive) were randomized to receive either entecavir (0.5 mg once daily) or lamivudine (100 mg once daily). Paired liver biopsy and serum samples were collected both at baseline and week 48 of treatment. Total intrahepatic HBV DNA and cccDNA were measured by the Invader® assay.1 Serum HBV DNA was measured by the COBAS Amplicor HBV Monitor Test. RESULTS: This is an interim report for the 14 HBeAg-positive patients. (The findings of the 26 anti-HBe-positive patients will be analyzed later.) For the 14 HBeAg-positive patients, 7 were randomized to receive entecavir, while the rest received lamivudine. CONCLUSION: The preliminary results of this study showed that 1 year of entecavir was superior to lamivudine in suppression of total intrahepatic and ccc DNA in liver biopsies. The addition of the data from the 26 anti-HBe patients may confirm these results.
Persistent Identifierhttp://hdl.handle.net/10722/101972
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, RMFen_HK
dc.contributor.authorNgai, WSen_HK
dc.contributor.authorKwok, CLen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-25T20:11:55Z-
dc.date.available2010-09-25T20:11:55Z-
dc.date.issued2005en_HK
dc.identifier.citationThe 56th Annual Meeting and Postgraduate Course of the American Association of Liver Diseases (AASLD), San Francisco, CA., 11-15 November 2005. In Hepatology, 2005, v. 42 suppl. S1, p. 573A, abstract no. 960en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/101972-
dc.description.abstractBACKGROUND: Two phase 3, multicenter, double-blind trials on HBeAg-positive and HBeAg-negative patients demonstrate that, compared with lamivudine, entecavir is superior in inducing histologic improvement, serum HBV DNA suppression and transaminase normalization. Since intrahepatic HBV DNA and covalently closed circular (ccc) DNA are important for control of viral replication, the efficacy of entecavir vs. lamivudine in achieving suppression of these entities should be studied. METHODS AND PATIENTS: The patients involved in this study were recruited from patients participating in the two phase 3 entecavir trials at our center in Hong Kong. Forty chronic hepatitis B patients (14 HBeAg-positive and 26 anti-HBe-positive) were randomized to receive either entecavir (0.5 mg once daily) or lamivudine (100 mg once daily). Paired liver biopsy and serum samples were collected both at baseline and week 48 of treatment. Total intrahepatic HBV DNA and cccDNA were measured by the Invader® assay.1 Serum HBV DNA was measured by the COBAS Amplicor HBV Monitor Test. RESULTS: This is an interim report for the 14 HBeAg-positive patients. (The findings of the 26 anti-HBe-positive patients will be analyzed later.) For the 14 HBeAg-positive patients, 7 were randomized to receive entecavir, while the rest received lamivudine. CONCLUSION: The preliminary results of this study showed that 1 year of entecavir was superior to lamivudine in suppression of total intrahepatic and ccc DNA in liver biopsies. The addition of the data from the 26 anti-HBe patients may confirm these results.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology . Copyright © John Wiley & Sons, Inc.en_HK
dc.titleOne-year treatment of entecavir results in reduction in intrahepatic covalently closed circular DNA levelen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=42 &issue=4 suppl 1&spage=573A&epage=&date=2005&atitle=One-year+treatment+of+entecavir+results+in+reduction+in+intrahepatic+covalently+closed+circular+DNA+levelen_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailNgai, WS: vinngai@HKUCC.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.20926-
dc.identifier.hkuros130904en_HK
dc.identifier.volume42en_HK
dc.identifier.issuesuppl. S1en_HK
dc.identifier.spage573A, abstract no. 960en_HK
dc.identifier.epage573A, abstract no. 960-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats